Expiring patents can be a catalyst for M&A in the life sciences industry as pharmaceutical and biotechnology companies seek to maintain revenue streams and competitive advantages. In this edition of Beyond the Deal, Proskauer lawyers assess the evolving landscape, share insights on the impacts of strategic deals and explain how they can shape the future of drug development and commercialization.
Read the full article: How Are Expiring Patents Fueling M&A in the Life Sciences Industry? //
Source: https://www.lexology.com/library/detail.aspx?g=5b464804-3079-48f2-9f3b-62ddddcee4e5